JP2018525354A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018525354A5 JP2018525354A5 JP2018500605A JP2018500605A JP2018525354A5 JP 2018525354 A5 JP2018525354 A5 JP 2018525354A5 JP 2018500605 A JP2018500605 A JP 2018500605A JP 2018500605 A JP2018500605 A JP 2018500605A JP 2018525354 A5 JP2018525354 A5 JP 2018525354A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- region
- cdr1
- cdr2
- cdr3 sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 106
- 239000003814 drug Substances 0.000 claims description 104
- 108010023337 axl receptor tyrosine kinase Proteins 0.000 claims description 43
- 229940127089 cytotoxic agent Drugs 0.000 claims description 43
- 229940124597 therapeutic agent Drugs 0.000 claims description 28
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 27
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 27
- 201000001441 melanoma Diseases 0.000 claims description 27
- 230000035772 mutation Effects 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 239000002254 cytotoxic agent Substances 0.000 claims description 26
- 201000011510 cancer Diseases 0.000 claims description 25
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 24
- 150000001413 amino acids Chemical group 0.000 claims description 22
- 229960002465 dabrafenib Drugs 0.000 claims description 19
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 19
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 19
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims description 18
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical group CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 18
- 239000002246 antineoplastic agent Substances 0.000 claims description 17
- 229960003862 vemurafenib Drugs 0.000 claims description 17
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 16
- 229960001433 erlotinib Drugs 0.000 claims description 16
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 16
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 16
- 229940121742 Serine/threonine kinase inhibitor Drugs 0.000 claims description 12
- 229930012538 Paclitaxel Natural products 0.000 claims description 11
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 11
- 229960001592 paclitaxel Drugs 0.000 claims description 11
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 11
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 11
- 229940125431 BRAF inhibitor Drugs 0.000 claims description 10
- 101150022345 GAS6 gene Proteins 0.000 claims description 10
- 108091000080 Phosphotransferase Proteins 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 230000005764 inhibitory process Effects 0.000 claims description 10
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 10
- 102000020233 phosphotransferase Human genes 0.000 claims description 10
- 229960004066 trametinib Drugs 0.000 claims description 10
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical group CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 8
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 8
- 230000000981 bystander Effects 0.000 claims description 8
- 229960003668 docetaxel Drugs 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 108010093470 monomethyl auristatin E Proteins 0.000 claims description 8
- 229940124647 MEK inhibitor Drugs 0.000 claims description 7
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims description 4
- MSNVESLISHTIRS-UHFFFAOYSA-N 9h-pyrrolo[2,1-c][1,4]benzodiazepine Chemical compound N1=C2C=CC=CC2=CN2CC=CC2=C1 MSNVESLISHTIRS-UHFFFAOYSA-N 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 4
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 229960001686 afatinib Drugs 0.000 claims description 4
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 4
- 238000012575 bio-layer interferometry Methods 0.000 claims description 4
- 229960004562 carboplatin Drugs 0.000 claims description 4
- 190000008236 carboplatin Chemical compound 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- 229960004679 doxorubicin Drugs 0.000 claims description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 4
- 229960005420 etoposide Drugs 0.000 claims description 4
- 229960002584 gefitinib Drugs 0.000 claims description 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 4
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 229960004891 lapatinib Drugs 0.000 claims description 4
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 4
- 229960003105 metformin Drugs 0.000 claims description 4
- 108010059074 monomethylauristatin F Proteins 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 claims description 3
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 claims description 3
- 238000010494 dissociation reaction Methods 0.000 claims description 3
- 230000005593 dissociations Effects 0.000 claims description 3
- 229940043355 kinase inhibitor Drugs 0.000 claims description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 3
- GTBCXYYVWHFQRS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)pentanoate Chemical compound C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CCC1=O GTBCXYYVWHFQRS-UHFFFAOYSA-N 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 229940126161 DNA alkylating agent Drugs 0.000 claims description 2
- 239000012624 DNA alkylating agent Substances 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 102100031487 Growth arrest-specific protein 6 Human genes 0.000 claims description 2
- 101000923005 Homo sapiens Growth arrest-specific protein 6 Proteins 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 2
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims description 2
- 241000282567 Macaca fascicularis Species 0.000 claims description 2
- 229930126263 Maytansine Natural products 0.000 claims description 2
- 102000029749 Microtubule Human genes 0.000 claims description 2
- 108091022875 Microtubule Proteins 0.000 claims description 2
- 230000004988 N-glycosylation Effects 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- YZDJQTHVDDOVHR-UHFFFAOYSA-N PLX-4720 Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(Cl)=CN=C3NC=2)=C1F YZDJQTHVDDOVHR-UHFFFAOYSA-N 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 229940123237 Taxane Drugs 0.000 claims description 2
- 102000004243 Tubulin Human genes 0.000 claims description 2
- 108090000704 Tubulin Proteins 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 108010044540 auristatin Proteins 0.000 claims description 2
- 229930195731 calicheamicin Natural products 0.000 claims description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 2
- 229960002173 citrulline Drugs 0.000 claims description 2
- 229960005061 crizotinib Drugs 0.000 claims description 2
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims description 2
- 239000003431 cross linking reagent Substances 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims description 2
- 229930188854 dolastatin Natural products 0.000 claims description 2
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims description 2
- 229960005501 duocarmycin Drugs 0.000 claims description 2
- 229930184221 duocarmycin Natural products 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 229940121647 egfr inhibitor Drugs 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 2
- 229960002411 imatinib Drugs 0.000 claims description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 claims description 2
- 210000004688 microtubule Anatomy 0.000 claims description 2
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 claims description 2
- 239000002777 nucleoside Substances 0.000 claims description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- -1 rakermycin (CC-1065) Chemical compound 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 claims description 2
- 229960001796 sunitinib Drugs 0.000 claims description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 1
- 108060006698 EGF receptor Proteins 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 229950010895 midostaurin Drugs 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 19
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940122558 EGFR antagonist Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021088877A JP7428680B2 (ja) | 2015-07-10 | 2021-05-27 | 癌治療用のａｘｌ特異的抗体－薬物コンジュゲート |
| JP2024009200A JP2024038480A (ja) | 2015-07-10 | 2024-01-25 | 癌治療用のａｘｌ特異的抗体－薬物コンジュゲート |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2015/065900 WO2016005593A1 (en) | 2014-07-11 | 2015-07-10 | Antibodies binding axl |
| EPPCT/EP2015/065900 | 2015-07-10 | ||
| US201662278283P | 2016-01-13 | 2016-01-13 | |
| US62/278,283 | 2016-01-13 | ||
| PCT/EP2016/066353 WO2017009258A1 (en) | 2015-07-10 | 2016-07-08 | Axl-specific antibody-drug conjugates for cancer treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021088877A Division JP7428680B2 (ja) | 2015-07-10 | 2021-05-27 | 癌治療用のａｘｌ特異的抗体－薬物コンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018525354A JP2018525354A (ja) | 2018-09-06 |
| JP2018525354A5 true JP2018525354A5 (cg-RX-API-DMAC7.html) | 2019-08-15 |
| JP6892431B2 JP6892431B2 (ja) | 2021-06-23 |
Family
ID=57756861
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018500605A Expired - Fee Related JP6892431B2 (ja) | 2015-07-10 | 2016-07-08 | 癌治療用のａｘｌ特異的抗体−薬物コンジュゲート |
| JP2018536482A Pending JP2019509257A (ja) | 2016-01-13 | 2017-01-13 | 癌治療用のａｘｌ特異的抗体−薬物コンジュゲート |
| JP2021088877A Active JP7428680B2 (ja) | 2015-07-10 | 2021-05-27 | 癌治療用のａｘｌ特異的抗体－薬物コンジュゲート |
| JP2021207104A Withdrawn JP2022037170A (ja) | 2016-01-13 | 2021-12-21 | 癌治療用のａｘｌ特異的抗体－薬物コンジュゲート |
| JP2024009200A Pending JP2024038480A (ja) | 2015-07-10 | 2024-01-25 | 癌治療用のａｘｌ特異的抗体－薬物コンジュゲート |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018536482A Pending JP2019509257A (ja) | 2016-01-13 | 2017-01-13 | 癌治療用のａｘｌ特異的抗体−薬物コンジュゲート |
| JP2021088877A Active JP7428680B2 (ja) | 2015-07-10 | 2021-05-27 | 癌治療用のａｘｌ特異的抗体－薬物コンジュゲート |
| JP2021207104A Withdrawn JP2022037170A (ja) | 2016-01-13 | 2021-12-21 | 癌治療用のａｘｌ特異的抗体－薬物コンジュゲート |
| JP2024009200A Pending JP2024038480A (ja) | 2015-07-10 | 2024-01-25 | 癌治療用のａｘｌ特異的抗体－薬物コンジュゲート |
Country Status (22)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114621347A (zh) | 2014-07-11 | 2022-06-14 | 根马布股份公司 | 结合axl的抗体 |
| PT3319993T (pt) * | 2015-07-10 | 2020-04-22 | Genmab As | Conjugados de anticorpo-fármaco específicos de axl para tratamento de cancro |
| KR20180101479A (ko) | 2016-01-13 | 2018-09-12 | 젠맵 에이/에스 | 항체 및 그의 약물 접합체를 위한 제제 |
| JP7030066B2 (ja) | 2016-05-26 | 2022-03-04 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | Ｅｇｆｒ阻害剤化合物 |
| WO2018007592A1 (en) | 2016-07-08 | 2018-01-11 | Genmab A/S | New dosage regimens for antibody drug conjugates based on anti-axl antibodies |
| EP3515446B1 (en) | 2016-09-19 | 2023-12-20 | Novartis AG | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| DK3618875T3 (da) | 2017-05-02 | 2023-07-10 | Novartis Ag | Kombinationsterapi omfattende en raf-inhibitor og trametinib |
| US11859252B2 (en) * | 2017-09-08 | 2024-01-02 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| WO2019051586A1 (en) * | 2017-09-13 | 2019-03-21 | National Research Council Of Canada | AXL SPECIFIC ANTIBODIES AND USES THEREOF |
| WO2019197506A1 (en) * | 2018-04-10 | 2019-10-17 | Genmab A/S | Axl-specific antibodies for cancer treatment |
| CN110483639A (zh) | 2018-05-15 | 2019-11-22 | 复旦大学 | 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途 |
| CN110540592B (zh) * | 2018-05-29 | 2022-08-09 | 杭州尚健生物技术有限公司 | 结合axl蛋白的抗体及其应用 |
| EP3856783A1 (en) * | 2018-09-26 | 2021-08-04 | Genmab A/S | Axl-specific antibodies for treatment of non-small cell lung cancer |
| US12258400B2 (en) * | 2019-03-20 | 2025-03-25 | Imcheck Therapeutics Sas | Antibodies having specificity for BTN2 and uses thereof |
| US20220177593A1 (en) * | 2019-03-29 | 2022-06-09 | Celldex Therapeutics, Inc. | Anti-axl antibodies and methods of use thereof |
| KR102881316B1 (ko) | 2019-05-13 | 2025-11-05 | 노파르티스 아게 | 암 치료를 위한 raf 억제제로서의 n-(3-(2-(2-하이드록시에톡시)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-2 (트리플루오로메틸)이소니코틴아미드의 새로운 결정질 형태 |
| WO2021154156A1 (en) * | 2020-01-31 | 2021-08-05 | Agency For Science, Technology And Research | Anti-axl antibody and uses thereof |
| CN115210263A (zh) * | 2020-02-28 | 2022-10-18 | 西福根有限公司 | 抗axl抗体和组合物 |
| JP2023525100A (ja) * | 2020-05-12 | 2023-06-14 | ノバルティス アーゲー | Ｃｒａｆ阻害剤を含む治療的組み合わせ |
| WO2022026807A2 (en) * | 2020-07-30 | 2022-02-03 | Albert Einstein College Of Medicine | Antibodies targeting sars-cov-2 and uses thereof |
| AU2021376286A1 (en) * | 2020-11-06 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Raf inhibitor for treating low grade glioma |
| JP2024505935A (ja) | 2021-01-29 | 2024-02-08 | イリミス セラピューティクス インコーポレーテッド | 非炎症性食細胞作用誘導活性を有する融合分子 |
| CN117177754A (zh) * | 2021-02-19 | 2023-12-05 | 首日生物制药公司 | Raf抑制剂和mek抑制剂的组合 |
| WO2024178140A1 (en) * | 2023-02-22 | 2024-08-29 | Resolute Science, Inc. | Compositions and methods for targeting tumor-associated macrophages |
| WO2024178139A1 (en) * | 2023-02-22 | 2024-08-29 | Resolute Science, Inc. | Compositions and methods for targeting tumor-associated macrophages |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US761218A (en) | 1899-10-05 | 1904-05-31 | U S Standard Voting Machine Co | Register or counter. |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| EP0486622B1 (en) | 1989-08-09 | 1998-11-04 | Rhomed, Incorporated | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| EP0593592B1 (en) | 1991-07-08 | 1998-03-25 | The University Of Massachusetts At Amherst | Thermotropic liquid crystal segmented block copolymer |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| IL144084A0 (en) | 1999-02-03 | 2002-05-23 | Biosante Pharmaceuticals Inc | Therapeutic calcium phosphate particles and methods of manufacture and use |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| CA2380813A1 (en) | 1999-07-29 | 2001-02-08 | Medarex, Inc. | Human monoclonal antibodies to her2/neu |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US7087600B2 (en) | 2001-05-31 | 2006-08-08 | Medarex, Inc. | Peptidyl prodrugs and linkers and stabilizers useful therefor |
| PT1523496E (pt) | 2002-07-18 | 2011-09-29 | Merus B V | Produção de misturas de anticorpos de forma recombinante |
| EP2353611B1 (en) | 2002-07-31 | 2015-05-13 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| US7705045B2 (en) | 2002-11-14 | 2010-04-27 | Syntarga, B.V. | Prodrugs built as multiple self-elimination-release spacers |
| KR101520209B1 (ko) | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
| WO2007018431A2 (en) | 2005-08-05 | 2007-02-15 | Syntarga B.V. | Triazole-containing releasable linkers and conjugates comprising the same |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EA016609B1 (ru) | 2005-11-28 | 2012-06-29 | Генмаб А/С | Рекомбинантные моновалентные антитела и способы их получения |
| RU2489423C2 (ru) | 2006-02-02 | 2013-08-10 | Синтарга Б.В. | Водорастворимые аналоги сс-1065 и их конъюгаты |
| CA2646508A1 (en) | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| EP1999154B1 (en) | 2006-03-24 | 2012-10-24 | Merck Patent GmbH | Engineered heterodimeric protein domains |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| EP2070956A1 (en) | 2007-12-14 | 2009-06-17 | Total Petrochemicals Research Feluy | Process for the production of a bimodal polypropylene having low ash content |
| AU2008265984B2 (en) | 2007-06-21 | 2014-07-17 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| CA2695297C (en) | 2007-08-01 | 2017-03-21 | Syntarga B.V. | Substituted cc-1065 analogs and their conjugates |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| SG186000A1 (en) * | 2007-11-12 | 2012-12-28 | U3 Pharma Gmbh | Axl antibodies |
| TW200936160A (en) | 2007-11-15 | 2009-09-01 | Chugai Pharmaceutical Co Ltd | Monoclonal antibodies that bind to anexelekto and uses thereof |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| JP5397668B2 (ja) | 2008-09-02 | 2014-01-22 | ソニー株式会社 | 記憶素子および記憶装置 |
| PT2344478T (pt) | 2008-11-03 | 2017-11-28 | Syntarga Bv | Análogos de cc-1065 e seus conjugados |
| MX2011006416A (es) | 2008-12-19 | 2011-07-12 | Macrogenics Inc | Diacuerpos covalentes y sus usos. |
| CA2759233C (en) | 2009-04-27 | 2019-07-16 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| EP2430050A1 (en) | 2009-05-11 | 2012-03-21 | U3 Pharma GmbH | Humanized axl antibodies |
| WO2010131733A1 (ja) | 2009-05-15 | 2010-11-18 | 中外製薬株式会社 | 抗axl抗体 |
| KR20120027055A (ko) | 2009-06-26 | 2012-03-20 | 리제네론 파라마큐티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| CA2796181C (en) | 2010-04-20 | 2023-01-03 | Genmab A/S | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| JP6022444B2 (ja) | 2010-05-14 | 2016-11-09 | ライナット ニューロサイエンス コーポレイション | ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法 |
| RU2577986C2 (ru) | 2010-06-18 | 2016-03-20 | Дженентек, Инк. | Антитела против axl и способы их применения |
| PL2606064T3 (pl) | 2010-08-16 | 2015-07-31 | Novimmune Sa | Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał |
| MX340556B (es) | 2010-08-24 | 2016-07-14 | Roche Glycart Ag | Anticuerpos biespecificos activables. |
| WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| US9249228B2 (en) | 2011-06-22 | 2016-02-02 | Oribase Pharma | Anti-Axl antibodies and uses thereof |
| CA2839480A1 (en) | 2011-06-22 | 2012-12-27 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-axl antibodies and uses thereof |
| EP2589609A1 (en) | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
| WO2013090776A1 (en) | 2011-12-15 | 2013-06-20 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of axl/gas6 signaling in the treatment of disease |
| ES2816078T3 (es) | 2011-12-20 | 2021-03-31 | Medimmune Llc | Polipéptidos modificados para armazones de anticuerpo biespecífico |
| ES2740749T3 (es) | 2012-04-20 | 2020-02-06 | Merus Nv | Métodos y medios para la producción de moléculas heterodiméricas similares a Ig |
| ES2734259T3 (es) | 2012-05-15 | 2019-12-05 | Concortis Biosystems Corp | Conjugados de fármacos, métodos de conjugación y usos de los mismos |
| AR093357A1 (es) * | 2012-11-05 | 2015-06-03 | Pf Medicament | Proteinas de union al antigeno y su utilizacion como producto de direccionamiento para el tratamiento del cancer |
| US20150315552A1 (en) | 2012-12-14 | 2015-11-05 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL Signaling in Primary Tumor Therapy |
| US20160097370A1 (en) * | 2013-03-26 | 2016-04-07 | James L. Rodgers | High-torque wind turbine |
| JP2016518382A (ja) * | 2013-04-26 | 2016-06-23 | ピエール、ファーブル、メディカマン | Ａｘｌ抗体薬物複合体および癌の治療のためのその使用 |
| US10028958B2 (en) * | 2014-04-19 | 2018-07-24 | Massachusetts Institute Of Technology | Methods of treating cancer with a combination of selected MEK1/2 and AXL inhibitors |
| GB201410825D0 (en) * | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| CN114621347A (zh) * | 2014-07-11 | 2022-06-14 | 根马布股份公司 | 结合axl的抗体 |
| PT3319993T (pt) * | 2015-07-10 | 2020-04-22 | Genmab As | Conjugados de anticorpo-fármaco específicos de axl para tratamento de cancro |
-
2016
- 2016-07-08 PT PT167390798T patent/PT3319993T/pt unknown
- 2016-07-08 LT LTEP16739079.8T patent/LT3319993T/lt unknown
- 2016-07-08 HU HUE16739079A patent/HUE049072T2/hu unknown
- 2016-07-08 KR KR1020187004011A patent/KR20180033523A/ko not_active Ceased
- 2016-07-08 EA EA201890272A patent/EA201890272A1/ru unknown
- 2016-07-08 SI SI201630699T patent/SI3319993T1/sl unknown
- 2016-07-08 DK DK16739079.8T patent/DK3319993T3/da active
- 2016-07-08 CN CN201680052378.3A patent/CN108368171A/zh active Pending
- 2016-07-08 SM SM20200359T patent/SMT202000359T1/it unknown
- 2016-07-08 JP JP2018500605A patent/JP6892431B2/ja not_active Expired - Fee Related
- 2016-07-08 CA CA2991805A patent/CA2991805A1/en active Pending
- 2016-07-08 AU AU2016292762A patent/AU2016292762B2/en active Active
- 2016-07-08 EP EP20151844.6A patent/EP3730520A1/en not_active Withdrawn
- 2016-07-08 ME MEP-2020-74A patent/ME03772B/me unknown
- 2016-07-08 HR HRP20200551TT patent/HRP20200551T1/hr unknown
- 2016-07-08 PL PL16739079T patent/PL3319993T3/pl unknown
- 2016-07-08 EP EP16739079.8A patent/EP3319993B1/en active Active
- 2016-07-08 WO PCT/EP2016/066353 patent/WO2017009258A1/en not_active Ceased
- 2016-07-08 US US15/742,818 patent/US20180326084A1/en not_active Abandoned
- 2016-07-08 RS RS20200419A patent/RS60141B1/sr unknown
- 2016-07-08 ES ES16739079T patent/ES2784685T3/es active Active
-
2017
- 2017-01-13 CN CN201780017252.7A patent/CN108884165A/zh active Pending
- 2017-01-13 ES ES17701812T patent/ES3029907T3/es active Active
- 2017-01-13 CA CA3010887A patent/CA3010887A1/en active Pending
- 2017-01-13 EP EP17701812.4A patent/EP3402822B1/en active Active
- 2017-01-13 US US16/069,395 patent/US20190022243A1/en not_active Abandoned
- 2017-01-13 EA EA201891607A patent/EA201891607A1/ru unknown
- 2017-01-13 CN CN202310359872.6A patent/CN116617410A/zh active Pending
- 2017-01-13 WO PCT/EP2017/050718 patent/WO2017121877A1/en not_active Ceased
- 2017-01-13 AU AU2017206967A patent/AU2017206967B2/en active Active
- 2017-01-13 JP JP2018536482A patent/JP2019509257A/ja active Pending
-
2018
- 2018-01-08 IL IL256790A patent/IL256790B/en active IP Right Grant
- 2018-06-17 IL IL260065A patent/IL260065A/en unknown
-
2020
- 2020-04-13 CY CY20201100339T patent/CY1123983T1/el unknown
- 2020-06-03 US US16/891,796 patent/US20200397913A1/en active Pending
-
2021
- 2021-05-27 JP JP2021088877A patent/JP7428680B2/ja active Active
- 2021-12-21 JP JP2021207104A patent/JP2022037170A/ja not_active Withdrawn
-
2022
- 2022-09-30 US US17/957,302 patent/US20230321261A1/en active Pending
- 2022-10-28 AU AU2022259847A patent/AU2022259847C1/en active Active
-
2024
- 2024-01-25 JP JP2024009200A patent/JP2024038480A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018525354A5 (cg-RX-API-DMAC7.html) | ||
| JP2024161445A (ja) | 抗体－薬物コンジュゲートとキナーゼ阻害剤の組み合わせ | |
| JP2020525542A5 (cg-RX-API-DMAC7.html) | ||
| HRP20200551T1 (hr) | Axl-specifični konjugati protutijelo-lijek za liječenje raka | |
| JP2025041725A (ja) | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ | |
| JP6581279B2 (ja) | 抗ｆｏｌｒ１免疫抱合体投薬レジメン | |
| JPWO2020130125A5 (cg-RX-API-DMAC7.html) | ||
| US9233171B2 (en) | Method of treatment of tumors that are resistant to EGFR antibody therapies by EGFR antibody cytotoxic agent conjugate | |
| JP2017522871A5 (cg-RX-API-DMAC7.html) | ||
| JP2024075668A (ja) | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ | |
| JP2019112403A (ja) | 抗ｈｅｒ２抗体−薬物コンジュゲート | |
| BR112019015950A2 (pt) | conjugados de anticorpo anti-ccr7 e fármaco | |
| CN115969970A (zh) | Abcg2抑制剂与sacituzumab govitecan的组合 | |
| HRP20200283T1 (hr) | Protutijela koja se vežu na axl | |
| AU2017234163A1 (en) | NaPi2b-targeted antibody-drug conjugates and methods of use thereof | |
| JP2018524295A (ja) | 抗体及び免疫複合体 | |
| JP2019524713A5 (cg-RX-API-DMAC7.html) | ||
| CN116390772A (zh) | 新型美登素类似物作为adc有效载荷及其在癌症治疗中的用途 | |
| CN118994402A (zh) | 针对pmel17的抗体及其缀合物 | |
| KR20190068550A (ko) | 항-c met 항체-세포독성 약물 컨쥬게이트의 의학적 용도 | |
| WO2024145398A1 (en) | Antibody drug conjugates | |
| JPWO2019197506A5 (cg-RX-API-DMAC7.html) | ||
| WO2024219442A1 (ja) | 抗体－薬物コンジュゲートと他の薬剤との組み合わせ | |
| WO2024050031A2 (en) | Novel camptothecin derivatves as antibody-drug conjugates (adc) payloads | |
| WO2024193570A9 (en) | Combination of antibody-drug conjugate and cancer therapy, and use thereof |